Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$198.4M
7 rounds on record
Latest round
$102M
Series D · Jul 2024 · 2 yr ago
Team
267
US Form 5500 (plan participants) · Dec 2025 · +35% in a year
Backers
2
Bezos Expeditions, Lumira Ventures
The money's age
Long since its last round
25 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 13
Certified HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization · businesswire.com
2025
Team of 267 was 198 · US Form 5500 (plan participants)
Jul 31, 2024
Raised a round Series D $102M · SEC Form D
Dec 12, 2022
Took on debt financing $85M · SEC Form D
Apr 15, 2020
Raised a round Venture round $40.8M · SEC Form D
Apr 5, 2019
Raised a round Venture round $47.4M · SEC Form D
Apr 18, 2018
Took on debt financing $7M · SEC Form D
Apr 18, 2018
Took on debt financing $7M · SEC Form D
Jan 30, 2017
Raised a round Venture round $8.3M · SEC Form D
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series D | Jul 2024 | $102M | — | SEC Form D |
| Debt Financing | Dec 2022 | $85M | — | SEC Form D |
| Venture round | Apr 2020 | $40.8M | — | SEC Form D |
| Venture round | Apr 2019 | $47.4M | — | SEC Form D |
| Debt Financing | Apr 2018 | $7M | — | SEC Form D |
| Debt Financing | Apr 2018 | $7M | — | SEC Form D |
| Venture round | Jan 2017 | $8.3M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | HistoSonics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Michael BlueExecutive Officer, DirectorSEC Form D
M. GibbonsExecutive OfficerSEC Form D
Akhil TripathiExecutive OfficerSEC Form D
Jon FreemanExecutive OfficerSEC Form D
Josh KingExecutive OfficerSEC Form D
Dan BulverExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Lumira Ventures Similar startupsby what they do, their industry and backers
Owlo is a deep-tech company developing the next generation of non-invasive microscopy for healthcare.
PAXAFE's platform provides end-to-end visibility capable of answering who, what, when, where and how for all your shipments.
NeuroHarmonics is developing non-invasive deep-brain neuromodulation with focused ultrasound — precise, reversible access to the deep…
ReddyPort is an innovation that enables oral access for better non-invasive ventilation care without interrupting patient therapy.
Draupnir Bio is developing new innovative therapies for patients.
The CUE1 and CUE1+ by Charco Neurotech offers a novel, non-invasive approach to increasing quality of life for people with Parkinson's.
News
HistoSonics Opens Expanded Histotripsy Training Center in Hong Kong
HistoSonics announced the opening of its expanded Histotripsy Training Center in Hong Kong, reinforcing the city's position as a leading hub for physician education, clinical collaboration, and innovation in Asia. The post HistoSonics Opens Expanded Histo
Read more
Report
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization
HistoSonics announced that the company has received CE Mark approval in Europe for its Edison System, enabling commercialization of the company's non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. The post HistoSon
Read more
Report
HistoSonics Announces Financing with Participation from Yosemite Among Other Strategic Investors
HistoSonics, the developer of the Edison Histotripsy System and novel histotripsy therapy platforms, today announced the closing of a new financing round with participation from Reed Jobs and Yosemite, whose aim is to "make cancer non-lethal in our lifeti
Read more
Report
HistoSonics Receives Landmark TFDA Approval in Taiwan, Accelerating Global Expansion
HistoSonics, the developer of the Edison Histotripsy System and novel histotripsy therapy platform, today announced it has received approval from the Taiwan Food and Drug Administration (TFDA) for the Edison System, representing a significant milestone in
Read more
Report
HistoSonics seeks FDA de novo authorization in kidney cancer
Investors including Bezos Expeditions and Thiel Bio supported HistoSonics' expansion plans last year by participating in a $250 million financing round.
Read more
Report
Pro access
Upgrade to see all 22 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
People
Michael Blue
Executive Officer, Director
M. Gibbons
Executive Officer
Akhil Tripathi
Executive Officer
Jon Freeman
Executive Officer
Josh King
Executive Officer
Dan Bulver
Executive Officer
Mike Daniel
Executive Officer
Richard Bosler
Executive Officer
Robert Morff
Director
Andrew Von Eschenbach
Director
Fred Lee Jr.
Director
Renard Charity
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Ann Arbor
United States
HQ
Financials
Total raised
$297.4M
Latest round
Series D
Funding rounds
7